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AbsTrACT
Objective To determine the comparative efficacy 
and safety of corticosteroids in the prevention of 
bronchopulmonary dysplasia (BPD) in preterm infants.
study design We systematically searched PubMed, 
EMBASE and the Cochrane Library. Two reviewers 
independently selected randomised controlled trials 
(RCTs) of postnatal corticosteroids in preterm infants. A 
Bayesian network meta-analysis and subgroup analyses 
were performed.
results We included 47 RCTs with 6747 participants. 
The use of dexamethasone at either high dose or low 
dose decreased the risk of BPD (OR 0.29, 95% credible 
interval (CrI) 0.14 to 0.52; OR 0.58, 95% CrI 0.39 to 
0.76, respectively). High-dose dexamethasone was 
more effective than hydrocortisone, beclomethasone 
and low-dose dexamethasone. Early and long-term 
dexamethasone at either high dose or low dose 
decreased the risk of BPD (OR 0.11, 95% CrI 0.02 to 
0.4; OR 0.37, 95% CrI 0.16 to 0.67, respectively). There 
were no statistically significant differences in the risk 
of cerebral palsy (CP) between different corticosteroids. 
However, high-dose and long-term dexamethasone 
ranked lower than placebo and other regimens in terms 
of CP. Subgroup analyses indicated budesonide was 
associated with a decreased risk of BPD in extremely 
preterm and extremely low birthweight infants (OR 0.60, 
95% CrI 0.36 to 0.93).
Conclusions Dexamethasone can reduce the risk of 
BPD in preterm infants. Of the different dexamethasone 
regimens, aggressive initiation seems beneficial, 
while a combination of high-dose and long-term use 
should be avoided because of the possible adverse 
neurodevelopmental outcome. Dexamethasone and 
inhaled corticosteroids need to be further evaluated in 
large-scale RCTs with long-term follow-ups.
InTrOduCTIOn
Bronchopulmonary dysplasia (BPD) is the most 
common serious pulmonary disease in prema-
ture infants.1 Approximately 20% of infants born 
at <30 weeks of gestation or with a weight <1500 
g are diagnosed with BPD. In addition, the inci-
dence of BPD appears to be growing in conjunc-
tion with the increased survival of infants with low 
birth weight.2–4 Premature infants with BPD are at 
an increased risk of death, and survivors often have 
lifelong morbidities, including delayed neurocogni-
tive development.5 
Postnatal systemic corticosteroid administration 
is controversial, mainly because of the concern 
for its adverse neurological effects.6–12 There were 
conflicting results from studies assessing the effects 
of diminished corticosteroid administration on the 
incidence and severity of BPD following the 2002 
policy statements of the American Academy of 
Pediatrics (AAP).13–15 Although the AAP revised the 
statement in 2010, the role of corticosteroids in the 
management of BPD remains uncertain.16 However, 
clinicians still use corticosteroids in approximately 
5%–32% of preterm infants to prevent and treat 
BPD.17 Therefore, identifying the optimal cortico-
steroid and regimen remains clinically relevant and 
important.18 19
New clinical trials, meta-analyses and follow-up 
studies have been published since 2010, warranting 
an updated review of the available information. 
Due to different comparators used in clinical trials, 
a pair-wise meta-analysis cannot be used to eval-
uate comparative effects of different corticosteroids 
and regimens. Therefore, we conducted a network 
meta-analysis of all relevant randomised evidence 
to comprehensively compare and rank the different 
corticosteroids used to prevent BPD.
What is already known on this topic?
 ► Systemic postnatal corticosteroids could reduce 
the risk of bronchopulmonary dysplasia (BPD) in 
preterm infants.
 ► Clinicians remain confused as to the 
corticosteroid to choose, the time to initiate and 
the dose to give.
What this study adds?
 ► For preterm infants with risk of BPD, high-dose 
dexamethasone appears to be more effective 
than other corticosteroids.
 ► The comparison between different 
dexamethasone regimens supports aggressive 
initiation but cautions against high-dose and 
long-term administration because of adverse 
neurodevelopmental outcome.
 ► Budesonide is associated with decreased risk 
of BPD in extremely preterm and extremely low 
birthweight infants.
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MeThOds
study search and selection
We systematically searched PubMed (1966 to June 2016), 
EMBASE (1974 to June 2016) and the Cochrane Library (Issue 
6, 2016) to identify relevant randomised controlled trials (RCTs) 
in humans published in English. We also manually searched the 
reference lists of retrieved trials and systematic reviews (online 
supplementary appendix 1).20 Two reviewers independently 
assessed the trials for eligibility and included RCTs that evalu-
ated the safety and efficacy of postnatal corticosteroid use for 
BPD prevention in preterm infants (<37 weeks). Studies that 
used postnatal surfactant and corticosteroids together were also 
included. Studies that assessed the combined use of corticoste-
roids and beta agonists were excluded.21
data extraction and quality assessment
The primary outcome assessed was BPD at 36 weeks’ post-
menstrual age (PMA). Secondary outcomes included BPD at 
28 days’ postnatal age (PNA), death at 36 weeks’ PMA and 28 
days PNA, and a diagnosis of cerebral palsy (CP) in a long-term 
follow-up. Two independent reviewers extracted the baseline 
characteristics, methods and outcomes of the included studies. 
Patients were categorised by gestational weeks (extremely 
preterm: <28 weeks; preterm: 28–37 weeks) and by birth 
weight (extremely low birth weight: <1000 g; very low birth 
weight: 1000–1500 g; low birth weight: 1500–2500 g). Dexa-
methasone regimens were categorised by the timing of initia-
tion (early initiation: ≤7 days’ PNA; late initiation: >7 days’ 
PNA), total dose (low dose: ≤3.0 mg/kg; high dose: >3.0 mg/
kg) and duration (short term: ≤3 days; long term: >3 days).22 
Intention-to-treat analysis data were used whenever available. 
We contacted the authors of the included studies for missing 
data by email. Two independent reviewers assessed the risk of 
bias in trials using the Cochrane risk of bias tool, with any 
discrepancies resolved by consensus.20
statistical analysis
We conducted a Bayesian network meta-analysis using 
the WinBUGS V.1.4.3 software (MRC Biostatistics Unit, 
Cambridge, UK) and adopted a random-effects model with 
vague priors for multiarm trials.23 24 Pooled estimates and the 
probability of each treatment being the best were obtained by 
the Markov chain Monte Carlo method. Model convergence 
was assessed by trace plots and Brooks-Gelman-Rubin plots.25 
The results of dichotomous outcomes were reported as poste-
rior medians or ORs with 95% credible intervals (CrIs). The 
surface under the cumulative ranking curve (SUCRA) was 
calculated as a percentage to estimate the probability that 
an intervention was the best.26 Prespecified subgroup anal-
yses were performed according to gestational age and birth 
weight.27 The interactions between the intervention effect 
and subgroups were assessed using a heterogeneity test in 
meta-analysis.28 29 Network geometry was performed with 
STATA V.13.0 software, in which the size of the nodes and 
thickness of the edges were proportional to sample sizes and 
numbers of trials involved, respectively.
resulTs
literature search
Of the 557 citations initially identified by searching bibli-
ographical databases, 449 were excluded through title and 
abstract screening. We examined the full text of 108 reports, 
and identified 66 publications describing 47 RCTs that were 
eligible for network meta-analysis (online supplementary 
appendix 2). We contacted 19 corresponding authors of 
the included studies with missing data, and received addi-
tional data from 6 of the 19 authors (online supplementary 
appendix 3).
Characteristics of the included studies
The included trials evaluated five corticosteroids and involved 
a total of 6747 randomly assigned participants. The sample 
Figure 1 Network of corticosteroids for the prevention of bronchopulmonary dysplasia at 36 weeks’ postmenstrual age. The circle size reflects the 
number of participants, and the line width reflects the number of direct comparisons. No connecting line between two treatments indicates that there 
was no direct comparison.
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size of the trials ranged from 23 to 856 participants (median 
60). The included studies recruited preterm infants with 
similar ranges of gestational age and birth weight, including 
extremely preterm with birth weights <1000 g (gestational 
age: median 26.7, IQR 26.0–27.9; birth weight: median 850, 
IQR 790–1010). According to data from 15 (31.9%) of the 
included trials, the average PNA at study entry ranged from 
0.14 to 27 days (median 8, IQR 3.04–15.50). Thirty-eight 
(80.9%) of the 47 trials reported the use of prenatal corti-
costeroids in mothers, and 36 (76.6%) reported the use of 
surfactant after birth in newborns (online supplementary 
appendix 4).
risk of bias
In approximately 65% of the trials, the risk of selection bias 
(sequence generation and allocation concealment) was deter-
mined to be low. Blinding of both participants and outcome 
assessors occurred in 21 trials (44.7%). Incomplete data were 
appropriately tackled for the primary outcome (BPD), with 
73.3% (33/45) assessed as having a low risk of bias. Forty-two 
trials (89%) were at a low risk of selective outcome reporting. 
Ten trials (20%) were deemed to have a high risk of other biases, 
for reasons that include early trial termination30–36 and unbal-
anced patient characteristics at baseline (online supplementary 
appendix 5).37 38
network comparisons of the different corticosteroids
Efficacy: BPD and death
Networks of eligible comparisons for the prevention of BPD are 
presented in figure 1. Nine (32.1%) of the 28 available pair-wise 
comparisons showed direct evidence supporting BPD prevention 
at 36 weeks’ PMA. The results of network comparisons for BPD 
Table 1 Results of network meta-analysis: relative effects of different corticosteroids versus placebo on BPD and CP
Outcomes
direct drug comparison studies/participants 
(n/n)
Or: median (95% CrI)
direct evidence All evidence
Network estimates for different corticosteroids
BPD at 36 weeks’ PMA
  Dexamethasone (high dose) 6/659 0.34 (0.20 to 0.57) 0.29 (0.14 to 0.52)
  Dexamethasone (low dose) 13/2180 0.66 (0.54 to 0.80) 0.59 (0.39 to 0.77)
  Hydrocortisone 5/1022 0.80 (0.61 to 1.05) 0.74 (0.43 to 1.14)
  Budesonide 2/886 0.60 (0.45 to 0.81) 0.58 (0.29 to 1.06)
  Fluticasone 1/53 0.32 (0.08 to 1.29)
  Beclomethasone 3/352 0.78 (0.46 to 1.35) 0.81 (0.40 to 1.55)
Cerebral palsy
  Dexamethasone (high dose) 5/307 2.30 (1.22 to 4.36) 2.02 (0.60 to 4.67)
  Dexamethasone (low dose) 3/245 0.61 (0.28 to 1.34) 0.81 (0.26 to 3.13)
  Hydrocortisone 3/334 1.09 (0.57 to 2.11) 1.79 (0.64 to 15.96)
  Beclomethasone 1/56 1.47 (0.12 to 18.47)
Network estimates for different dexamethasone regimens
BPD at 36 weeks’ PMA
  Dexamethasone—LHL 2/148 0.38 (0.19 to 0.76) 0.33 (0.09 to 1.03)
  Dexamethasone—LHS 0 NR 0.26 (0.02 to 2.66)
  Dexamethasone—LLL 5/231 0.63 (0.25 to 1.57) 0.65 (0.22 to 1.63)
  Dexamethasone—EHL 3/140 0.12 (0.04 to 0.40) 0.11 (0.02 to 0.41)
  Dexamethasone—EHS 1/88 0.91 (0.39 to 2.10) 0.91 (0.19 to 4.24)
  Dexamethasone—ELL 2/106 0.56 (0.43 to 0.75) 0.37 (0.16 to 0.67)
  Dexamethasone—ELS 5/1022 0.76 (0.56 to 1.02) 0.77 (0.39 to 1.53)
Cerebral palsy
  Dexamethasone—LHL 2/123 2.38 (0.95 to 5.98) 2.75 (0.88 to 8.01)
  Dexamethasone—LLL 1/56 0.67 (0.20 to 2.28) 0.87 (0.22 to 3.70)
  Dexamethasone—EHL 1/146 2.23 (0.92 to 5.40) 2.30 (0.41 to 13.22)
  Dexamethasone—LHS 1/22 0.16 (0.01 to 4.69) 0.10 (1.66E-04 to 3.56)
  Dexamethasone—ELL 1/144 0.63 (0.24 to 1.65) 0.53 (0.14 to 1.93)
BPD, bronchopulmonary dysplasia; CrI, credible interval;NR, not reported; EHL, early initiation of dexamethasone prevention (≤7 days after birth) with a high total dose (>3.0 mg/kg) and a long-term 
duration (>3 days); EHS, early initiation of dexamethasone prevention (≤7 days after birth) with a high total dose (>3.0 mg/kg) and a short-term duration (≤3 days); ELL, early initiation of dexamethasone 
prevention (≤7 days after birth) with a low total dose (≤3.0 mg/kg) and a long-term duration (>3 days); ELS, early initiation of dexamethasone prevention (≤7 days after birth) with a low total dose 
(≤3.0 mg/kg) and a short-term duration (≤3 days); LHL, late initiation of dexamethasone prevention (>7 days after birth) with a high total dose (>3.0 mg/kg) and a long-term duration (>3 days); LHS, 
late initiation of dexamethasone prevention (>7 days after birth) with a high total dose (>3.0 mg/kg) and a short-term duration (≤3 days); LLL, late initiation of dexamethasone prevention (>7 days after 
birth) with a low total dose (≤3.0 mg/kg) and a long-term duration (>3 days); PMA, postmenstrual age.





36 weeks’ PMA 
(%)
death at 
36 weeks’ PMA 
(%) CP (%)
Dexamethasone (high dose) 91.2 74.1 26.9
Dexamethasone (low dose) 56.0 64.5 76.8
Budesonide 54.9 23.8 – 
Fluticasone 78.8 47.1 – 
Beclomethasone 28.0 – 46.6
Placebo 6.9 40.5 – 
Hydrocortisone 34.2 – 31.4
*Larger SUCRA values denote more effective interventions.
BPD, bronchopulmonary dysplasia; CP, cerebral palsy; PMA, postmenstrual age; 
SUCRA, surface under the cumulative ranking curve.
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and CP are shown in table 1, and the results for other outcomes 
are available in online supplementary appendix 6A .
The use of dexamethasone, at either high or low dose, 
decreased the risk of BPD compared with placebo (OR 0.29, 
95% CrI 0.14 to 0.52; OR 0.58, 95% CrI 0.39 to 0.76, respec-
tively). High-dose dexamethasone was associated with a lower 
risk of BPD at 36 weeks’ PMA, as compared with hydrocortisone 
(OR 2.53, 95% CrI 1.20 to 5.68), beclomethasone (OR 2.75, 
95% CrI 1.23 to 6.78) and low-dose dexamethasone (OR 1.99, 
95% CrI 1.04 to 3.91) (online supplementary appendix 6A). 
According to the estimated probability of being the best for BPD 
prevention at 36 weeks’ PMA, high-dose dexamethasone ranked 
first (91.2%) and beclomethasone ranked last (28.0%) (table 2).
In terms of mortality, all corticosteroids failed to show any 
superiority compared with placebo, and no statistically signif-
icant difference was found between different corticosteroids 
(online supplementary appendix 6A).
Safety: CP
Compared with placebo, high-dose dexamethasone, hydrocor-
tisone and beclomethasone tended to have a higher risk of CP, 
although the difference was statistically non-significant (ORs 
ranging from 1.47 to 2.02). No statistically significant difference 
was found between the five corticosteroids (online supplemen-
tary appendix 6A). According to SUCRA probabilities, low-dose 
dexamethasone was the first (76.8%), ranked higher than hydro-
cortisone, while high-dose dexamethasone was the last (26.9%).
Of note, two dexamethasone trials and three hydrocor-
tisone trials were discontinued early due to safety consid-
erations.29 31–34 Of the five prematurely terminated trials, 
two were stopped due to an increased incidence of spon-
taneous gastrointestinal perforation in participants of the 
trials,31 32 while the others were terminated because of the 
serious adverse effects reported in other studies and in the 
2002 statement from the AAP.31 35 36
Comparisons of different dexamethasone regimens
We compared different regimens of dexamethasone, one of 
commonly used corticosteroids in clinical practice, to determine 
its optimal regimen.39
Efficacy: BPD and death
Compared with placebo, early-initiation, high-dose, long-term 
(EHL), and early-initiation, low-dose, long-term (ELL) dexa-
methasone regimens were associated with a decreased risk of 
BPD at 36 weeks’ PMA (OR 0.11, 95% CrI 0.02 to 0.41; OR 
0.37, 95% CrI 0.16 to 0.67) (table 1). In addition, EHL was 
more effective than early-initiation, low-dose, short-term (OR 
7.24, 95% CrI 1.60 to 43.15), early-initiation, high-dose, short-
term (OR 8.56, 95% CrI 1.14 to 82.62), and late-initiation, 
low-dose, long-term (LLL) (OR 6.07, 95% CrI 1.09 to 37.88). 
No statistically significant differences were found between 
different dexamethasone regimens in terms of mortality (online 
supplementary appendix 6B).
Safety: CP
No statistically significant differences in the risk of CP were 
detected between different dexamethasone regimens (online 
supplementary appendix 6B). According to SUCRA probabil-
ities, high-dose and long-term regimens,late-initiation, high-
dose, long-term (LHL) and EHL, ranked lower than placebo 
in terms of CP (online supplementary appendix 7).
results of subgroup analyses
By gestational week
For extremely preterm infants, both doses of dexamethasone 
and budesonide were effective in decreasing the risk of BPD at 
36 weeks’ PMA compared with placebo (OR 0.06, 95% CrI 0.01 
to 0.33; OR 0.73, 95% CrI 0.55 to 0.97; OR 0.60, 95% CrI 
0.36 to 0.93), even though budesonide failed to show efficacy 
in general preterm infants. Moreover, high-dose dexamethasone 
was superior to low-dose dexamethasone and budesonide in 
this population (OR 11.48, 95% CrI 2.16 to 93.39; OR 9.29, 
95% CrI 1.63 to 79.07). No statistically significant difference 
was found in terms of mortality and CP between the five corti-
costeroids (online supplementary appendix 8).
By birth weight
For extremely low birthweight infants, only budesonide signifi-
cantly reduced the risk of BPD at 36 weeks’ PMA compared 
with placebo (OR 0.60, 95% CrI 0.34 to 0.95). For very low 
birthweight infants, both doses of dexamethasone were associ-
ated with a decreased risk of BPD at 36 weeks’ PMA (high dose: 
OR 0.23, 95% CrI 0.07 to 0.56; low dose: OR 0.36, 95% CrI 
0.16 to 0.70). There were no statistically significant differences 




Our network meta-analysis provides unified hierarchies of 
evidence for corticosteroid use in BPD, overcoming the problem 
due to inadequate evidence from head-to-head trials. Compared 
with placebo, both high-dose and low-dose dexamethasone 
reduced the risk of BPD at 36 weeks’ PMA. In addition, high-
dose dexamethasone significantly decreased the risk of BPD 
compared with hydrocortisone and beclomethasone. The attempt 
to explore the optimal regimens of dexamethasone revealed that 
early initiation and a high dose of dexamethasone decreased the 
risk of BPD, but high-dose and long-term dexamethasone might 
increase the risk of CP. For the extremely preterm and extremely 
low birthweight infants, budesonide showed a decreased risk of 
BPD, compared with placebo.
hydrocortisone versus dexamethasone
The AAP guideline discussed the difference between hydrocor-
tisone and dexamethasone in terms of safety, based mainly on 
pharmacokinetic studies and animal studies.16 Our study showed 
that hydrocortisone ranked lower than low-dose dexamethasone 
in terms of both CP and BPD prevention at 36 weeks’ PMA. 
According to a recent in vivo experimental study, hydrocortisone 
had similar neurotoxic effects to dexamethasone on neurons 
in immature chicken cerebellum and it may not be safer than 
dexamethasone.40
different dexamethasone regimens
High-dose, long-term dexamethasone regimens appeared to 
be associated with a higher risk of CP compared with placebo 
(ORs range from 2.30 to 2.75) and low-dose, short-term regi-
mens (ORs range from 2.30 to 33.33), but without significant 
differences. In addition, our findings appeared to support early 
initiation, as both EHL and ELL were associated with a lower 
risk of CP compared with LHL and LLL (OR: 0.82 and 0.62, 
respectively). The possible explanations for the finding include 
the following: early-initiation, low-dose dexamethasone was 
found to suppress the expression of inflammatory mediators 
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and decrease pulmonary oedema.41 The adverse neurodevel-
opmental outcomes of postnatal dexamethasone therapy were 
shown to be associated with initiation time. Early initiation of 
dexamethasone enhanced the acquisition of contextual fear and 
spatial memory later in life of rat pups and increased dendritic 
spine number.42 Hence, our findings challenge the use of high-
dose and long-term dexamethasone, but advocate a more aggres-
sive initiation of dexamethasone than current clinical practice.
extremely preterm and low birth weight
In subgroup analyses, high-dose dexamethasone was shown to 
be superior to low-dose dexamethasone, hydrocortisone and 
beclomethasone in extremely preterm infants. However, the 
recommendation of an increase in dose for extremely preterm 
could not be made due to the lack of evidence on long-term 
neurodevelopmental safety. It was found that budesonide signifi-
cantly reduced BPD at 36 weeks’ PMA compared with placebo in 
extremely preterm and extremely low birthweight infants. This 
finding was consistent with the point raised by Bassler,43 who 
predicted that inhaled budesonide may play a role in extremely 
low birthweight infants. However, there was no convincing 
evidence from RCTs on the effects of other inhaled corticoste-
roids for BPD prevention.11 44
limitations of this study
Our study has several potential limitations. First, variations 
in corticosteroid regimens and participants resulted in signifi-
cant heterogeneity across the included studies. We therefore 
planned a comparison of the different regimens of dexameth-
asone and prespecified subgroup analyses by gestational week 
and birth weight. Second, missing data on the exact dose and 
time of outcome measures reduced the number of trials included 
in the network meta-analysis. In addition, patient enrolment 
was halted early in seven of the included trials. Five trials were 
terminated due to adverse reactions,31 33–36 while the other two 
were terminated because of difficulties in participant recruit-
ment.30 32 Given the limited number of studies, we did not 
conduct sensitivity analysis on the excluded terminated trials. 
Finally, the effects of corticosteroids on adverse neurodevelop-
mental outcomes remained unclear due to the lack of trials with 
long-term follow-ups.
COnClusIOns
For preterm infants with risk of BPD, dexamethasone can reduce 
the risk of BPD, and high-dose dexamethasone is more effica-
cious than other regimens of corticosteroids. Of the different 
dexamethasone regimens, aggressive initiation seems a favour-
able option, and a combination of high-dose and long-term use 
should be avoided because of the possible long-term adverse 
neurodevelopmental outcome. Budesonide is associated with 
a decreased risk of BPD in extremely preterm and extremely low 
birthweight infants, although recommendations cannot be made 
due to the lack of long-term safety data. RCTs of early-initiation 
and low-dose dexamethasone, budesonide and other inhaled 
corticosteroids with factorial design and long-term follow-ups 
are urgently needed to identify the optimal postnatal corticoste-
roid regimens.
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